Innopharma LLC Aug. 8 announced that the Food and Drug Administration has approved its generic version of UCB Inc.'s Keppra (levetiracetam) injection.
Keppra is indicated as adjunctive therapy in the treatment of certain types of seizures associated with epilepsy, according to FDA.
Piscataway, N.J.-based Innopharma said it has entered into an agreement with X-GEN Pharmaceuticals Inc. for marketing and distribution of this product in the United States.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.